ZETAMET SETTABLE
Dead / Abandoned — Abandoned — no statement of use filed (as of 10 Oct 2025)
What this means for you
This application is over — abandoned 10 Oct 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97301062
- Mark type
- Stylized text
- Filed
- 08 Mar 2022
- Published for opposition
- 02 Aug 2022
- Abandoned
- 10 Oct 2025
- Attorney of record
- Katherine P. Califa
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical products for the treatment of bone diseases; pharmaceutical preparations for the treatment of metastatic tumors and lesions; Pharmaceuticals, namely, for destroying, inhibiting or preventing the spread of uncontrolled growth of abnormal tissues, namely, metastatic tumors and lesions
Owner
- Zetagen Therapeutics, Inc., Syracuse, NY, US
- Zetagen Therapeutics, Inc., Syracuse, NY, US
Prosecution history
- 10 Oct 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 10 Oct 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 21 Aug 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 21 Aug 2024 — SOU EXTENSION 4 GRANTED
- 21 Aug 2024 — SOU EXTENSION 4 FILED
- 21 Aug 2024 — SOU TEAS EXTENSION RECEIVED
- 21 Feb 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 20 Feb 2024 — SOU EXTENSION 3 GRANTED
- 20 Feb 2024 — SOU EXTENSION 3 FILED
- 20 Feb 2024 — SOU TEAS EXTENSION RECEIVED
- 07 Nov 2023 — ASSIGNED TO EXAMINER
- 16 Sept 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 14 Sept 2023 — SOU EXTENSION 2 GRANTED
- 14 Sept 2023 — SOU EXTENSION 2 FILED
- 14 Sept 2023 — SOU TEAS EXTENSION RECEIVED